The extended credit facility removes near-term refinancing risk and provides committed liquidity through 2031. Monitor upcoming quarterly filings for leverage ratio and covenant compliance, as the reduced facility size may signal conservative capital management. No immediate catalyst for stock movement.
Price Chart
Executive Summary
Anika Therapeutics entered into a Fifth Amendment to its existing credit agreement with Bank of America on July 10, 2026, reducing the revolving facility to $50 million and extending the maturity to July 10, 2031. The amendment includes a potential $50 million accordion feature, SOFR-based pricing with a spread of 0.25%-1.25%, and financial covenants (max leverage 3.50x, min interest coverage 3.00x). This is a routine refinancing that provides extended liquidity without material new financial data.
Key Facts
- Revolving credit facility reduced to $50 million (from an undisclosed prior amount) with a maturity date of July 10, 2031.
- Company may request up to an additional $50 million in commitments, subject to lender approval, for a maximum of $100 million.
- Interest rate is SOFR plus 0.25% to 1.25% based on consolidated leverage ratio; commitment fee is 0.20% to 0.30% per annum.
- Financial covenants: maximum Consolidated Net Leverage Ratio of 3.50x (stepping to 4.00x for material acquisitions) and minimum Consolidated Interest Coverage Ratio of 3.00x.
- Lenders hold a first-priority lien on substantially all assets of the company.
Financial Impact
No new borrowing or financial figures disclosed; facility size reduced to $50 million with extended maturity.
Risk Factors
- Potential covenant breach if leverage increases above 3.50x or interest coverage falls below 3.00x.
- Interest rate exposure from SOFR-based floating rate pricing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (ANIK) — Batch item 1 | 0001171843-26-004635 |
| Exhibit: exh_102.htm | 0001171843-26-004635 |
| Document: f8k_071426.htm | 0001171843-26-004635 |
| Document: 0001171843-26-004635-index-headers.html | 0001171843-26-004635 |
| Document: 0001171843-26-004635-index.html | 0001171843-26-004635 |
| Document: 0001171843-26-004635.txt | 0001171843-26-004635 |
| 8-K Filing (ANIK) — Batch item 7 | 0001171843-26-004635 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | 8-K | $16.17 $21.68 | ▲ +34.08% | ▲ +29.06% | $19.10 (+18.12%) |
Jul 14, 2026 11w ago | 8-K | $15.93 $22.03 | ▲ +38.29% | ▲ +35.95% | $19.10 (+19.90%) |
Jun 23, 2026 14w ago | 8-K | $14.73 $15.01 | ▲ +1.90% | ▼ −0.03% | $19.10 (+29.67%) |
Jun 11, 2026 16w ago | Institutional Cluster | $14.72 $15.60 | ▼ −5.98% | ▼ −4.20% | $19.10 (−29.76%) |
Jun 8, 2026 16w ago | DEFA14A | $14.60 $16.03 | ▲ +9.79% | ▲ +8.16% | $19.10 (+30.82%) |
Jun 1, 2026 17w ago | DEFA14A | $14.63 $14.63 | · 0.00% | ▲ +1.30% | $19.10 (+30.55%) |
Apr 30, 2026 22w ago | Insider Cluster | $12.45 $14.90 | ▲ +19.68% | ▲ +14.71% | $19.10 (+53.41%) |
Apr 29, 2026 22w ago | 8-K | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 28, 2026 22w ago | DEFA14A | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 15, 2026 24w ago | Press Release | $15.39 $14.80 | ▼ −3.83% | ▼ −9.65% | $19.10 (+24.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access